{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.6","value":"656"},{"groupId":"OG001","spread":"252","value":"357"},{"groupId":"OG002","spread":"449","value":"869"},{"groupId":"OG003","spread":"73.5","value":"655"},{"groupId":"OG004","spread":"658","value":"1210"},{"groupId":"OG005","spread":"2190","value":"1880"},{"groupId":"OG006","spread":"1160","value":"1730"},{"groupId":"OG007","spread":"1560","value":"1710"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"281","value":"1020"},{"groupId":"OG001","spread":"1090","value":"1380"},{"comment":"The SD could not be determined due to too few participants with available data at this time point.","groupId":"OG002","spread":"NA","value":"681"},{"groupId":"OG003","spread":"544","value":"839"},{"groupId":"OG004","spread":"659","value":"1420"},{"groupId":"OG005","spread":"1200","value":"888"},{"groupId":"OG006","spread":"722","value":"2050"},{"groupId":"OG007","spread":"1070","value":"2030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"description":"The mean AUClast of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.","dispersionType":"Standard Deviation","groups":[{"description":"In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.","id":"OG000","title":"Oprozomib IR 150 mg/Day + Dexamethsone"},{"description":"In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.","id":"OG001","title":"Oprozomib GR 150 mg/Day + Dexamethasone"},{"description":"In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG002","title":"Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone"},{"description":"In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG003","title":"Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone"},{"description":"In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG004","title":"Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone"},{"description":"In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG005","title":"Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone"},{"description":"In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG006","title":"Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone"},{"description":"In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.","id":"OG007","title":"Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.","reportingStatus":"POSTED","timeFrame":"Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose","title":"Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Oprozomib","type":"SECONDARY","unitOfMeasure":"hour*ng/mL"}